KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $5.0 million.

  • Acadia Pharmaceuticals' Other Accumulated Expenses fell 6069.63% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 6069.63%. This contributed to the annual value of $15.4 million for FY2024, which is 3957.05% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Other Accumulated Expenses stood at $5.0 million, which was down 6069.63% from $13.4 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Accumulated Expenses peaked at $15.4 million during Q4 2024, and registered a low of $986000.0 during Q2 2022.
  • For the 5-year period, Acadia Pharmaceuticals' Other Accumulated Expenses averaged around $7.0 million, with its median value being $5.9 million (2023).
  • In the last 5 years, Acadia Pharmaceuticals' Other Accumulated Expenses plummeted by 6533.05% in 2022 and then surged by 77784.43% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $2.7 million in 2021, then increased by 0.82% to $2.7 million in 2022, then soared by 307.53% to $11.0 million in 2023, then soared by 39.57% to $15.4 million in 2024, then crashed by 67.53% to $5.0 million in 2025.
  • Its Other Accumulated Expenses stands at $5.0 million for Q3 2025, versus $13.4 million for Q2 2025 and $9.3 million for Q1 2025.